Myungin Pharmaceutical is showing weakness during trading as profit-taking sell orders emerged following its recent stock price gains, despite the publication of a positive equity research report by a securities firm.

As of the morning session on the 18th, Myungin Pharmaceutical is trading at 440,150 won, down 1,200 won from the previous trading day.

On this day, KB Securities published a new report on Myungin Pharmaceutical titled 'Balan New Plant Nears Completion' and assigned an investment opinion of 'Not Rated.'

KB Securities evaluated Myungin Pharmaceutical as a specialized company for central nervous system (CNS) psychotropic drugs in South Korea. In particular, it analyzed that the increase in operating profit in the first quarter of this year was the result of improved cost ratios and streamlined selling and administrative expenses.

The securities firm cited two key growth drivers going forward. The first is the construction of the Balan 2nd Plant. Once the new plant is completed, it projected that solid dosage production capacity will expand, paving the way for entry into the pellet formulation contract development and manufacturing organization (CDMO) market.

The second is securing a new drug pipeline. The firm expects future improvement in performance through the expansion of the new drug business and strengthening of the product portfolio, as the company has secured exclusive domestic marketing rights for 'evenamide,' a candidate substance for treating schizophrenia.

The market is also showing strong interest in the fact that Myungin Pharmaceutical is working to expand its production capacity and secure a new drug pipeline based on its existing specialty pharmaceutical business. In particular, the assessment is that once the completion of the Balan 2nd Plant becomes a reality, enhanced production competitiveness and entry into new businesses are expected.

However, the stock price is showing a downward trend on this day due to the impact of profit-taking sell orders in line with short-term market movements. Investors are watching with key focus on the timing of the new plant's operation, the potential expansion of the CDMO business, and the progress of new drug-related development.

[※ This article was written with the assistance of AI. Investment decisions are the responsibility of the investor, and the content included in this article may change depending on market conditions.]